Organization
University of Chicago, Chicago, IL
6 abstracts
Abstract
Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.Org: Alliance Statistics and Data Management Center, Rochester, MN, University of Chicago, Chicago, IL, Georgetown University Hospital, Washington, DC, Helen F. Graham Cancer Center and Research Institute, Newark, DE, University of North Carolina, Chapel Hill, NC,
Abstract
A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.Org: Department of Medicine, University of Chicago, Johns Hopkins Medicine, University of Pennsylvania, Emory University Winship Cancer Institute, Hollings Cancer Center,
Abstract
ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.Org: South Australian Health and Medical Research Institute, Universitätsklinikum Jena, Akita University Hospital, The University of Texas MD Anderson Cancer Center, University of Chicago,
Abstract
The clinical relevance of margins in frameless stereotactic radiosurgery for intact brain metastases: A randomized trial of 0 vs 2 mm margins.Org: Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, Department of Radiation Oncology, University of Chicago, Chicago, IL, University of California, San Francisco, San Francisco, CA, The University of Chicago, Chicago, IL, Wilmot Cancer Institue, Rochester, NY,
Abstract
Streamlining regulatory review in a multicenter platform trial: Opportunity to enhance patient centered care and drive innovation and efficiency.Org: University of California, San Francisco, San Francisco, CA, University of California San Diego Ideker Laboratory, La Jolla, CA, Wake Forest, Winston-Salem, NC, University of California Berkeley, School of Public Health, Berkeley, CA, Alliance for Cancer Clinical Trials, Dana Farber Cancer Institute, I-SPY2, Wrentham, MA,
Abstract
ACTIVATION OF THE INTERFERON PATHWAY IS DEPENDENT UPON AUTOANTIBODIES IN AFRICAN AMERICAN SLE PATIENTS, BUT NOT IN EUROPEAN-AMERICAN SLE PATIENTS Org: University of Chicago, Chicago, IL, Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, United States,